Recombinant DNA technology Market By Product Type (Medical (Human Protein, Therapeutic Agent, and Vaccine) and Non-medical (Specialty Chemical, Biotech Crops, and Others)), By Component Type (Expression System (Mammalian, Bacteria, Yeast, Baculovirus/Insect, and Others) and Cloning Vector), By Application Type (Agriculture and Pharmaceuticals (Human, Animal, Environment, and Others)), By End User (Pharmaceutical Companies, Research Institutes, and Others), and By Region - Trends, Analysis and Forecast till 2034

Recombinant DNA technology Market accounted for USD 865.7 Billion in 2024 and is estimated to be USD 2768.9 Billion by 2034 and is anticipated to register a CAGR of 13.60%.

Recombinant DNA technology is a tool in gene therapy which involves combining DNA of two different species and incorporating it into a host in order to manipulate specific genes in an organism’s DNA in a precise and controlled manner. Over the past years, this space has witnessed tremendous achievement in the production of recombinant drugs and therapeutics without the help of human donors. Recombinant DNA technology has been used to develop numerous products, including vaccines, that have substantially improved the quality of human life.

Drivers and Restrains:

Regional Insights:

On region the target market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

• North America market is estimated to witness a significantly high revenue share over the forecast period due to rising investment and funding.

• Effective regulatory bodies
• Use of technology

• Asia Pacific market is estimated to witness a fastest revenue share over the forecast period.

• Rising Health Awareness
• Rising R&D investments

Dividing this target market into segments:

Recombinant DNA technology Market is segmented based on Product Type, Component Type, Application, End-user and Region.

Product Type Insight

On the basis of Product Type, the target market is segmented into Medical (Human Protein, Therapeutic Agent, and Vaccine) and Non-medical (Specialty Chemical, Biotech Crops, and Others

Component Type Insight

On the basis of Component Type, the target market is segmented into Expression System (Mammalian, Bacteria, Yeast, Baculovirus/Insect, and Others) and Cloning Vector.

Application Insight

On the basis of Application, the target market is segmented into Agriculture and Pharmaceuticals (Human, Animal, Environment, and Others.

End-user Insight

On the basis of End-user, the target market is segmented into Pharmaceutical Companies, Research Institutes, and Others.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032.

Key Players:

The key players operating the Recombinant DNA technology Market includes, Pfizer, Inc., F.Hoffmann-La Roche Ltd, Cibus, Ltd., New England Biolabs,Inc., Trofacgen,Inc., GenScript, Corporation, GlaxoSmithKline plc., Novo Nordisk A\S, Monsanto Company, Eli Lily and Company, Horizon Discovery Group PLC, Amgen Inc., and Novartis AG

Recent Development:

             The New Launched Product News,

• In March 2022, VBI Vaccines Inc. launched PreHevbrio (Recombinant Hepatitis B Vaccine) in the United States for the prevention of infection caused by all known subtypes of hepatitis B virus (HBV) in adults age 18 years and older.